Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Digital Health Center of Excellence

Digital Health Center of Excellence

                        Cybersecurity in Medical Devices Frequently Asked Questions (FAQs)
          Digital Health Frequently Asked Questions (FAQs)
          Digital Health Center of Excellence Services
          About the Digital Health Center of Excellence
          Network of Digital Health Experts
          What is Digital Health?
          Cybersecurity
          Digital Health Terms
          Guidances with Digital Health Content
          Digital Health Policy Navigator
          Digital Health Reports
          FDA Digital Health Advisory Committee
          Medical Device Interoperability
          Digital Health Research and Partnerships
          Augmented Reality and Virtual Reality in Medical Devices


                        Diagnostic Data Program
          Software as a Medical Device (SaMD)
          Device Software Functions Including Mobile Medical Applications
          Wireless Medical Devices
          Digital Health Software Precertification (Pre-Cert) Pilot Program Home
          Medical Devices
          Digital Health Center of Excellence
          CDRH seeks public comment: Digital Health Technologies for Detecting Prediabetes and Undiagnosed Type 2 DiabetesDigital Health Center of Excellence CDRH seeks public comment: Digital Health Technologies for Detecting Prediabetes and Undiagnosed Type 2 Diabetes
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintMany health care stakeholders are embracing digital health technologies (DHTs), including those enabled by artificial intelligence/machine learning (AI/ML), to transform the way health care is delivered in patients’ homes. However, the full potential of DHTs for the detection of prediabetes and undiagnosed diabetes, especially in diverse populations, particularly racial and ethnic minorities, has yet to be realized.

The U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) is uniquely positioned to advance the development of high-quality, safe, and effective medical devices, including DHTs, which can provide significant improvements in health care, quality of life, and wellness to diverse populations. CDRH is seeking to gather more information about how DHTs including AI/ML may help with early detection of risk factors for type 2 diabetes, prediabetes, and type 2 undiagnosed diabetes. This effort is consistent with CDRH’s 2022-2025 Strategic Priority focused on advancing health equity.

Request for Public Comment

In particular, CDRH seeks comment from the public on the following questions:

Community Engagement and Consortia Efforts

Which patient and community groups, health systems, pre-competitive consortia, or other organizations have prediabetes prevention, detection, or management programs?
	Are there any existing connected cohorts for people living with prediabetes? Connected cohorts are defined as groups of people with a common characteristic engaged longitudinally with digital technologies such as smartphones, apps, consumer wearables, or connected sensors for the purposes of health improvement or research. If so, how many people are members of the cohort and how are they “connected?”
	What existing research consortia are developing risk prediction models for pre-disease states including prediabetes?Science/Innovation

What DHTs, including those enabled by AI/ML algorithms, are currently being used outside the clinic to prevent, detect, treat, or reverse prediabetes?
	How are DHTs typically being used to capture various signals amongst people who have risk factors for type 2 diabetes, prediabetes, and undiagnosed type 2 diabetes, and what methods are being used to assess such signals as digitally derived measures of biomarkers?
	Who are key subpopulations of interest that might benefit the most from remote screening and diagnostic tools? Please include clinical and non-clinical considerations.
	What are high-prevalence and high-impact risk factors for prediabetes and undiagnosed type 2 diabetes that are or could be captured by DHTs?
	Are there any existing tools, datasets, or devices used for prediabetes detection? Are there any that are particularly indicated for individuals of a particular race, ethnicity, gender, language, and/or comorbid disability?
	Are there applications of using AI/ML on existing health care datasets (e.g., ECG, radiology datasets) that can be used for the detection of prediabetes and/or transition to type 2 diabetes?Outcomes

What patient and community-centered outcomes could be measured for prediabetes and undiagnosed type 2 diabetes (e.g., symptoms, activities of daily living, co-morbidities, hospitalizations, costs, psychosocial factors, etc.)?
	How can digitally derived measures of biomarkers be leveraged to improve the engagement, adherence, and self-management of people diagnosed with or at risk for prediabetes?Clinical Integration and Implementation

How can digitally derived measures of biomarkers be integrated into clinical decision support systems or electronic health records to identify undiagnosed type 2 diabetes or prediabetes?  What are some of the barriers and proposed solutions to implementation?
	How can EHR data and digitally derived measures be used to understand which patients with prediabetes reverse to a healthy state or transition to type 2 diabetes?
	Are there effective ongoing early screening and prevention efforts for prediabetes and undiagnosed type 2 diabetes that utilize DHTs?  If yes, please describe. If no, please describe what a solution would look like to enable such an effort.
	**Please submit all public comments to the docket (FDA-2023-N-4853), available at Regulations.gov. The public comment period will end on Feb. 29, 2024.**Submit Comments by February 29, 2024

Background

The FDA seeks to advance health equity by:

Facilitating availability of and access to medical technologies for all populations,
	Empowering people to make informed decisions regarding their healthcare,
	Supporting innovation of novel and existing technologies that address health inequities, and
	Reducing barriers to increase participation by diverse populations in evidence generation.Advancing health equity will ensure all patients, regardless of race, sexual orientation, gender identity, age, physical abilities, geographic location, educational background, and economic status will have access to safe, effective, and high-quality, medical technologies, including at home use devices, which may provide significant improvements in healthcare, quality of life, and wellness.

Questions

For questions contact  digitalhealth@fda.hhs.gov.

                                                                                  Content current as of:
      01/30/2024
              
              
Regulated Product(s)
		 Medical DevicesDigital Health Center of Excellence

          
                        Cybersecurity in Medical Devices Frequently Asked Questions (FAQs)
          Digital Health Frequently Asked Questions (FAQs)
          Digital Health Center of Excellence Services
          About the Digital Health Center of Excellence
          Network of Digital Health Experts
          What is Digital Health?
          Cybersecurity
          Digital Health Terms
          Guidances with Digital Health Content
          Digital Health Policy Navigator
          Digital Health Reports
          FDA Digital Health Advisory Committee
          Medical Device Interoperability
          Digital Health Research and Partnerships
          Augmented Reality and Virtual Reality in Medical Devices


                        Diagnostic Data Program
          Software as a Medical Device (SaMD)
          Device Software Functions Including Mobile Medical Applications
          Wireless Medical Devices
          Digital Health Software Precertification (Pre-Cert) Pilot Program
 Subscribe to Digital Health
                        Sign up to receive email updates about Digital Health.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop